Compare DexCom, Inc. (DXCM) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ralph Lauren Corp — how do they compare? DexCom, Inc. trades at $77.62 (market cap $28.06B), while Ralph Lauren Corp trades at $384.6 (market cap $22.26B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 1% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RL | |
|---|---|---|
Market Cap | $28.06B | $22.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $414.25 |
52-Week Low | $54.84 | $283.34 |
Enterprise Value | $27.03B | $23.21B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Ralph Lauren (RL) trades at $368.97, down 1.47% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.80 versus $2.55 expected, and robust profitability with a net income margin of 11.6% in 2025. Revenue growth accelerated to $7.08B in 2025, up from $6.6B in 2024, supported by digital expansion and brand momentum in Asia. Cash flow from operations remains healthy at $1.24B, though net cash flow moderated to $258.80M.
The investment outlook is positive given analyst consensus of $445.71 price target and 66% buy ratings, but near-term technical weakness and premium valuation (P/E of 24.76) pose risks. Key catalysts include continued execution of the Next Great Chapter strategy and DTC growth, while macro pressures and competitive intensity are headwinds. The stock offers growth exposure but requires monitoring of technical support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
